Announcements Trials

Browse Landscape

Phase

Status

Completed 5 Unknown 1 Terminated 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colonic Neoplasms 3 Adenoma 2 Venous Thromboembolism 1 Urinary Bladder Neoplasms 1 Thrombocytopenia 1 Soft Tissue Neoplasms 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Node Positive HER2 Negative Breast Cancer 1 Neoplasms, Plasma Cell 1 Neoplasm Metastasis 1 Myocardial Infarction 1 Multiple Myeloma 1 Hereditary Sensory and Autonomic Neuropathies 1 Hematuria 1 Hematologic Diseases 1 Glioblastoma 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1 Adenomatous Polyps 1 Adenocarcinoma of Lung 1 Acute Coronary Syndrome 1

Interventions

Dexamethasone 112 Bortezomib 61 Lenalidomide 49 Cyclophosphamide 49 Calcium Dobesilate 43 pomalidomide 32 Melphalan 31 fludarabine 25 Filgrastim 25 carfilzomib 22 fludarabine phosphate 21 daratumumab 20 Granulocyte Colony-Stimulating Factor 16 Whole-Body Irradiation 15 Antilymphocyte Serum 15 dexamethasone acetate 14 Mycophenolic Acid 14 Thalidomide 13 Tacrolimus 13 Cyclosporine 13 Busulfan 13 Peripheral Blood Stem Cell Transplantation 12 ixazomib 11 dexamethasone 21-phosphate 10 auricularum 10 pembrolizumab 9 Radiotherapy 9 Etoposide 9 belantamab mafodotin 8 Rituximab 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Multiple Myeloma × Aspirin × Clear all

NCT00790842 2018-10-24

PrE1003

PrECOG, LLC.

Phase 1/2 Terminated

63 enrolled 14 charts

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡